CCR2 and rheumatoid arthritis: Genetic ablation of CCR2 specifically within GMSC‐EVs abolished their joint‐specific accumulation and therapeutic efficacy, unequivocally establishing CCR2 as a critical molecular determinant for precision targeting in RA.